Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Recurrence 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 30Carboplatin 24Cisplatin 11Topotecan 8liposomal doxorubicin 6Hyperthermic Intraperitoneal Chemotherapy 6mirvetuximab soravtansine 5Cyclophosphamide 5Drug Therapy 4Chemotherapy, Adjuvant 4Bevacizumab 4rucaparib 3Peripheral Blood Stem Cell Transplantation 3Neoadjuvant Therapy 3Doxorubicin 3Docetaxel 3CP protocol 3olaparib 2liposomal amphotericin B 2Surgical Procedures, Operative 2Letrozole 2Gemcitabine 2trebananib 1trastuzumab deruxtecan 1phenoxodiol 1pembrolizumab 1oregovomab 1niraparib 1fluzoparib 1epothilone B 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Ovarian Epithelial × epothilone B × Clear all
NCT00262990 2020-12-17

Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer

Novartis

Phase 3 Completed
829 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡